Hepatitis C (HCV) is the most common cause of chronic liver disease and hepatocellular carcinoma, as well as the leading indication for liver transplantation in the Western world. For many ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given ...

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. The recommended single-agent dose is 400 mg orally twice a day ...

Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for adults with ...

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab ...